Volume | 175,606 |
|
|||||
News | - | ||||||
Day High | 23.745 | Low High |
|||||
Day Low | 22.26 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NewAmsterdam Pharma Company NV | NAMS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
22.42 | 22.26 | 23.745 | 22.70 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,511 | 175,606 | $ 23.05 | $ 4,046,898 | - | 5.6326 - 26.35 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:18:29 | 100 | $ 22.84 | USD |
NewAmsterdam Pharma Company NV Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 2.04B | - | - | - | -2,613.91 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NewAmsterdam Pharma Comp... News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NAMS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 22.20 | 23.745 | 21.763 | 22.57 | 164,125 | 0.64 | 2.88% |
1 Month | 24.99 | 24.99 | 20.29 | 22.36 | 168,987 | -2.15 | -8.60% |
3 Months | 12.25 | 26.35 | 11.5664 | 20.54 | 243,497 | 10.59 | 86.45% |
6 Months | 9.05 | 26.35 | 5.6326 | 16.56 | 172,149 | 13.79 | 152.38% |
1 Year | 13.51 | 26.35 | 5.6326 | 14.86 | 128,446 | 9.33 | 69.06% |
3 Years | 11.00 | 32.88 | 5.6326 | 14.53 | 108,032 | 11.84 | 107.64% |
5 Years | 11.00 | 32.88 | 5.6326 | 14.53 | 108,032 | 11.84 | 107.64% |
NewAmsterdam Pharma Comp... Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. |